Aljian Capital Management LLC Increases Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Aljian Capital Management LLC raised its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 4.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,400 shares of the company’s stock after purchasing an additional 375 shares during the period. Aljian Capital Management LLC’s holdings in GE HealthCare Technologies were worth $735,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in GEHC. LGT Financial Advisors LLC raised its holdings in GE HealthCare Technologies by 1,673.3% during the 3rd quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock valued at $25,000 after buying an additional 251 shares during the last quarter. Capital Performance Advisors LLP bought a new position in shares of GE HealthCare Technologies in the 3rd quarter worth approximately $26,000. Ashton Thomas Securities LLC purchased a new position in GE HealthCare Technologies during the third quarter valued at $26,000. Darwin Wealth Management LLC purchased a new position in GE HealthCare Technologies during the 3rd quarter valued at about $31,000. Finally, Continuum Advisory LLC boosted its position in shares of GE HealthCare Technologies by 101.8% in the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after purchasing an additional 168 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on GEHC shares. Wells Fargo & Company increased their price objective on shares of GE HealthCare Technologies from $95.00 to $96.00 and gave the company an “overweight” rating in a research report on Thursday, October 31st. Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and boosted their target price for the company from $95.00 to $103.00 in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.77.

GE HealthCare Technologies Stock Performance

Shares of GEHC opened at $85.90 on Thursday. The business has a 50-day simple moving average of $83.58 and a two-hundred day simple moving average of $85.39. The company has a quick ratio of 0.98, a current ratio of 1.23 and a debt-to-equity ratio of 1.12. GE HealthCare Technologies Inc. has a 52 week low of $74.51 and a 52 week high of $94.55. The stock has a market cap of $39.25 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 2.93 and a beta of 1.15.

GE HealthCare Technologies (NASDAQ:GEHC) last released its earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. On average, analysts expect that GE HealthCare Technologies Inc. will post 4.3 EPS for the current year.

GE HealthCare Technologies Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Tuesday, January 14th will be given a dividend of $0.035 per share. This represents a $0.14 annualized dividend and a dividend yield of 0.16%. This is an increase from GE HealthCare Technologies’s previous quarterly dividend of $0.03. The ex-dividend date of this dividend is Tuesday, January 14th. GE HealthCare Technologies’s dividend payout ratio (DPR) is presently 3.85%.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.